Consistent with these findings, RNA interference mediated or pharmacological inhibition of MET in sunitinib treated 786-O ccRCC reduced metastatic behavior and restored susceptibility to sunitinib [162]. Here, MET is linked to nonpapillary renal cell carcinoma.